

1 Iron status in a representative sample of US pregnant women is not associated with pre-
2 pregnancy BMI: results from the NHANES (1999-2010) study

3

4

5

6 Mihaela A. Ciulei¹, Kelly Gallagher², Djibril Ba³, Celeste Beck¹, Ruth A. Pobee⁴, Alison D.

7 Gernand¹, Rachel E. Walker^{1*}

8

9

10 ¹Department of Nutritional Sciences, The Pennsylvania State University, University Park,
11 Pennsylvania, United States of America

12 ²Ross and Carol Nese College of Nursing, The Pennsylvania State University, University Park,
13 Pennsylvania, United States of America

14 ³Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania,
15 United States of America

16 ⁴Department of Emergency Medicine, University of Illinois at Chicago, Chicago, Illinois, United
17 States of America

18

19 * Corresponding author:

20 E-mail: rew5009@psu.edu (REW)

21

22 **Abstract**

23 Iron deficiency in pregnancy is related to many poor health outcomes, including anemia and low
24 birth weight. A small number of previous studies have identified maternal body mass index
25 (BMI) as potential risk factors for poor iron status. Our objective was to examine the association
26 between pre-pregnancy BMI and iron status in a nationally representative sample of US adult
27 women. We used data from the National Health and Nutrition Examination Survey (NHANES;
28 1999-2010) for pregnant women ages 18-49 years (n=1156). BMI (kg/m²) was calculated using
29 pre-pregnancy weight (self-reported) and height (measured at examination). Iron deficiency (ID)
30 was defined as total body iron (calculated from serum ferritin and transferrin receptor using
31 Cook's equation) < 0 mg/kg and anemia as hemoglobin < 11 g/dL. Associations were examined
32 using weighted Poisson regression models, adjusted for confounders (age, race/ethnicity,
33 education, family income, and trimester). Approximately 14% of pregnant women had ID and
34 8% had anemia in this sample. There were no differences in the prevalence of ID or anemia in
35 women with pre-pregnancy overweight and obesity (ID: overweight, adjusted prevalence ratio
36 (PR)=1.28, 95%CI: 0.89-1.83; obesity, PR=0.75, 95%CI: 0.39-1.45; anemia: overweight,
37 PR=1.08, 95%CI: 0.53-2.19; obesity, PR=0.99, 95%CI: 0.49-2.01) compared to women with a
38 normal BMI. Findings from these US nationally representative data indicate that iron status in
39 pregnancy does not differ by pre-pregnancy BMI. Since iron deficiency during pregnancy
40 remains a significant public health concern, NHANES should consider measuring current iron
41 status in upcoming cycles.

42

43

44 **Introduction**

45 During pregnancy, iron deficiency (ID) increases the risk of anemia, low birth weight, and
46 infant mortality, while pre-pregnancy obesity increases the risk of Cesarean section, gestational
47 diabetes, and failure to initiate breastfeeding¹⁻⁴, among other outcomes. Both ID and obesity are
48 common in women of reproductive age in the US, especially in populations of minority race and
49 ethnicity^{5,6}.

50 The prevalence of ID increases from about 10% in non-pregnant women of reproductive age
51 to about 16-25% during pregnancy due to blood volume expansion and the increased iron needs
52 to meet fetal and placental demand⁷⁻¹⁰, making it a significant public health concern. The
53 severity of ID increases with higher parity^{7,8,11} and across gestation^{12,13}. Therefore, pregnancy
54 is a critical period for managing iron status in women of reproductive age. Based on data from
55 the National Health and Nutrition Examination Survey (NHANES) in the US, 18% of pregnant
56 women suffer from ID defined by total body iron⁹. However, these data are over 10 years old
57 since NHANES has not collected biomarkers of functional and circulating iron status combined
58 with gestational age data since 2010.

59 Similarly, obesity is growing in prevalence in the US population in general, including in
60 women of reproductive age. Based on a recent analysis of national data, the prevalence of
61 obesity in women of reproductive age was 29% in 2019⁶. Some prior studies have suggested that
62 women with obesity are especially vulnerable to the development of ID due to alterations in
63 metabolism and inflammatory signaling^{14,15}. A prior review article indicated that pre-pregnancy
64 obesity and overweight pose a risk for ID and ID with anemia (IDA) during pregnancy¹⁶.
65 However, obesity is highly confounded by a number of demographic factors at a population
66 level, making it imperative to conduct nation-wide investigations that can adjust for

67 socioeconomic variation. Given the high prevalence of pre-pregnancy obesity in the US ⁶ and the
68 importance of iron to promote a healthy pregnancy, a better understanding of the relationship
69 between these factors on a national level could help identify women at higher risk of ID.

70 Although there are previous studies in the US showing an association between obesity and
71 iron status ^{17,18}, to our knowledge, there are no studies examining iron status and body mass
72 index (BMI) in a US nationally representative sample of pregnant women. Previous studies were
73 performed with a small sample size ¹⁷, in other nations ^{19–22}, or in adolescents alone ¹⁸.

74 In this study, our objective was to examine iron status by pre-pregnancy BMI category in a
75 nationally representative sample of pregnant women in the US. Based on previous studies, we
76 hypothesized first, that women with pre-pregnancy overweight or obesity would have higher
77 rates of ID, anemia, and IDA during pregnancy compared to women with normal weight.

78 **Methods**

79 **Study population**

80 We conducted a cross-sectional analysis of maternal pre-pregnancy BMI and iron status
81 using data collected in the NHANES study (<https://www.cdc.gov/nchs/nhanes/index.htm>). We
82 selected the 1999-2010 cycles because they contain data on measured iron status biomarkers in
83 addition to pregnancy status, gestational age, and self-reported pre-pregnancy weight.
84 Additionally, these years oversampled pregnant women. In the 12 years (1999-2010; 6 cycles)
85 that we selected, there were 62,160 participants, of which 19,569 were between the ages of 18-49
86 years. Next, we restricted the dataset to include only pregnant women (n=1,414) with positive
87 survey sampling weights (n_missing=76), which resulted in a sample size of 1,338. We further
88 restricted the dataset to include complete observations for measured height (n_missing=6), self-
89 reported pre-pregnancy weight (n_missing=23), and iron and inflammation biomarkers

90 (n_missing=153). Therefore, the final analytic sample consisted of 1,156 participants. The
91 original NHANES protocol was approved by the National Center for Health Statistics' Research
92 Ethics Review Board ²³, and we used only data publicly available for download.

93 **Iron and acute inflammation biomarkers**

94 To characterize iron and inflammation status, NHANES collected maternal venous blood.
95 Hemoglobin (Hb) was measured in whole blood, and ferritin, transferrin receptor (TfR), and the
96 inflammatory biomarker, C-reactive protein (CRP) were measured in serum by NHANES study
97 personnel. Serum and blood samples were collected at a single visit during the mobile
98 examination phase of NHANES. A complete description of the protocol used in the collection of
99 the iron and inflammatory biomarkers can be found online
100 (<https://wwwn.cdc.gov/nchs/nhanes/default.aspx>).

101 Serum ferritin ^{24,25} and TfR ^{26,27} were analyzed using the immunoturbidimetric assay method
102 via Roche kits on a Hitachi 912 clinical analyzer for 1999-2008 samples, and on an Elecsys 170
103 for ferritin, ²⁸ and Hitachi Mod P for TfR ²⁹ for the 2009-2010 samples. Due to the use of
104 different technologies for assessment and following best-practice, we standardized ferritin
105 concentrations using the formula, $10^{(0.989*\log_{10}(\text{Hitatchi 912})+0.049)}$
106 (https://wwwn.cdc.gov/Nchs/Nhanes/2009-2010/TFR_F.htm). We calculated total body iron as
107 $[\log_{10}(\text{TfR}_{\text{Cook}} * 1000 / \text{adjusted Ferritin}) - 2.8229]$ where $\text{TfR}_{\text{Cook}} = 1.5 * \text{unadjusted TfR}_{\text{Roche}} + 0.35$
108 to match Cook's standard values ³⁰. We used the total body iron cutoff < 0 mg/kg to classify ID
109 ³⁰. We also defined ID as ferritin < 12 $\mu\text{g/L}$ ³¹ and TfR > 4.4 mg/L ³². NHANES measured Hb as
110 part of the complete blood count analysis using a quantitative cell counter (^{33,34} Beckman
111 Coulter, Brea, CA). We defined anemia as Hb < 11 g/dL, per Centers for Disease Control and
112 Prevention guidelines ³¹. The American College of Obstetricians and Gynecologists suggests

113 using a different cutoff (Hb < 10.5 g/dL) for anemia during 2nd trimester³⁵. However, we chose
114 to use a single cutoff due to the difficulty of classifying a large number of participants with
115 ‘unknown’ or missing trimester data (n=183). Instead, we have included trimester as a covariate
116 in all adjusted models. CRP was assessed with latex-enhanced nephelometry by NHANES^{36–38}
117 (Dade Behring Inc, Deerfield, IL). We defined inflammation as CRP > 5 mg/L³⁹. Ferritin is an
118 acute phase protein and therefore can change in response to inflammation. It is recommended to
119 adjust ferritin for inflammation with CRP and alpha(1)-acid glycoprotein using the BRINDA
120 method in this population^{40,41}. However, NHANES did not measure alpha(1)-acid glycoprotein
121 in the cycles we included. In addition, a linear relationship was not observed between log-
122 transformed ferritin and log-transformed CRP, suggesting that the BRINDA method was not
123 appropriate for this data⁴². Therefore, we did not adjust ferritin for inflammation, similar to the
124 approach taken by previous studies⁹. IDA was defined as anemia and ID using each iron
125 indicator separately (ferritin, TfR, and total body iron)⁴³.

126 **Body mass index**

127 We calculated pre-pregnancy BMI (kg/m²) based on pre-pregnancy weight (self-reported)
128 and height (measured to the nearest mm in the Mobile Examination Center). We used the
129 following BMI categories developed by the World Health Organization: underweight (< 18.5
130 kg/m²), normal (18.5-24.9 kg/m²), overweight (25-29.9 kg/m²), and obese (≥30 kg/m²)⁴⁴.

131 **Covariates**

132 Maternal and household characteristics were collected via demographic and reproductive
133 questionnaires. Based on prior literature^{7,9,11,45}, we identified maternal age, race/ethnicity,
134 maternal education, family income (NHANES calculated as poverty:income ratio)⁴⁶, and

135 pregnancy trimester as confounders for inclusion as covariates in our models. Parity was
136 considered but was not included due to high amounts of missing data (approximately 30%).

137 Maternal age and self-reported race/ethnicity variables did not have missing data. The
138 maternal age variable was used as continuous in the analyses. The race/ethnicity variable was
139 used as a categorical variable based on the NHANES created levels, Mexican American, Other
140 Hispanic, non-Hispanic White, non-Hispanic Black, and Other Race – Including Multi-Racial.
141 The ‘Other’ race category included participants selecting from various Asian, Pacific Islander,
142 and Native American categories, as well as those selecting multiple races. NHANES cycles from
143 1999-2006 oversampled Mexican-American ethnicity, and therefore estimates for Hispanic
144 ethnicity from those cycles represent primarily Mexican-American ethnicity
145 (<https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/99-10-analytic-guidelines.pdf>). Due
146 to small sample size in our current study, we combined the Mexican-American and Other
147 Hispanic categories into one Hispanic category. However, it should be noted that the Hispanic
148 category reliably represents only Mexican-American ethnicity from 1999-2006 (48).

149 There was one participant missing maternal education data, and this observation was
150 collapsed with the high school diploma or less category, resulting in the final category of ‘high
151 school diploma or less/unknown.’ Final maternal education categories were: high school diploma
152 or less/unknown, some college, and college graduate. There were eighty-nine participants with
153 missing family income data. These participants were coded as a separate unknown category. The
154 final income categories were: poverty:income ratio < 130%, poverty:income ratio \geq 130, and
155 unknown. Gestational age was self-reported as months in NHANES, and we used this
156 information to categorize participants as first trimester (0-3 months), second trimester (4-6
157 months), and third trimester (7-9 months). Participants who did not know their gestational age or

158 did not know they were pregnant were coded as unknown (n = 178). There were five participants
159 missing gestational age data, and these observations were collapsed with participants who
160 reported an unknown gestational age. Final trimester categories were: first trimester, second
161 trimester, third trimester, and unknown.

162 **Statistical analysis**

163 All data were analyzed using weighted statistics in SAS version 9.4 (Cary, NC) and Stata
164 version 18 (College Station, TX), as recommended by the NHANES website
165 (<https://www.cdc.gov/nchs/nhanes/index.htm>). Data merging, cleaning, and descriptive statistics
166 were performed in SAS, while adjusted models were performed in Stata. Survey methods were
167 used in both SAS and Stata to account for the complex sampling design of the NHANES survey,
168 including strata, cluster, and mobile examination center weights.

169 Descriptive statistics, including percentages and standard errors, were conducted in the total
170 sample and by the outcomes of interest, ID, anemia, and IDA, using weighted Chi-square tests.
171 For our primary analysis, ferritin, TfR, total body iron, and Hb were assessed by BMI category
172 and by continuous BMI. The iron biomarkers ferritin and TfR did not follow a normal
173 distribution, and thus were log transformed for analyses. Total body iron and Hb followed a
174 normal distribution and were not transformed. Associations between iron biomarker
175 concentrations and BMI (both continuous and categorical) were tested using weighted multiple
176 linear regression models adjusted for age, race/ethnicity, education level, family income, and
177 trimester of pregnancy. When analyzing BMI as a categorical variable, the Bonferroni
178 adjustment for multiple comparisons was used when performing pairwise comparisons.
179 Prevalence ratios and prevalence differences of ID, anemia, and IDA with their respective

180 confidence intervals were calculated by BMI category using Poisson regression models with
181 robust error variance.

182 All Poisson regression models calculating prevalence were performed with and without
183 covariates. Covariates included in all models were: age, race/ethnicity, education level, family
184 income, and trimester of pregnancy. If the number of cases was < 30 for any model, then the
185 estimates for those analyses were deemed unreliable and have been noted in the results ⁴⁷.

186 Statistical significance was defined as $p < 0.05$ for all models.

187 **Results**

188 **Overall Population Characteristics**

189 The mean (standard error) age for the pregnant women in this study was 28.0 (0.29) years.
190 Sample characteristics are reported in the total sample and by ID (based on total body iron),
191 anemia (based on Hb), and IDA (based on total body iron and Hb) in Table 1. Approximately
192 30% of women graduated from college and 24% had a family income below 130% of the poverty
193 to income ratio. Overall, approximately half of the sample size had a normal pre-pregnancy BMI
194 and were of non-Hispanic White race/ethnicity. The prevalence of ID (based on total body iron),
195 anemia, and IDA (based on total body iron and Hb) were 14%, 8%, and 3%, respectively, and the
196 prevalence of inflammation was 48% (S1 Table). The prevalence of ID, anemia, and IDA were
197 similar across most characteristics but were all highest during the third trimester and among non-
198 Hispanic Black women.

199 **Table 1: Characteristics of pregnant women (18-49 years of age) from NHANES 1999-2010 for the total sample, by iron**
 200 **deficiency, anemia, and iron deficiency anemia.**

Variables	Total Sample N=1156		Iron Deficiency ^a N=211		Anemia ^b N=100		IDA ^c N=49	
	N ^d	% (SE) ^e	N (cases)	% (SE)	N (cases)	% (SE)	N (cases)	% (SE)
Age groups								
18-24	428	31.7 (1.88)	100	17.6 (3.14)	36	7.65 (2.16)	21	4.12 (1.59)
25-29	352	28.7 (1.81)	66	16.4 (3.16)	34	7.36 (1.90)	16	2.47 (0.88)
30-34	258	23.2 (2.02)	34	14.3 (3.75)	19	7.40 (2.45)	7	2.14 (1.10)
35-49	118	16.4 (2.41)	11	3.44 (1.31)	11	7.88 (3.36)	5	1.43 (0.71)
Overall p-value				0.03		1.00		0.31
Race/Ethnicity								
Hispanic	401	22.3 (2.00)	89	17.5 (2.56)	38	8.35 (2.05)	21	3.07 (0.91)
NH White	512	53.2 (3.03)	72	10.6 (1.99)	25	3.28 (1.29)	14	1.66 (0.93)
NH Black	170	14.5 (1.89)	39	23.3 (4.30)	30	18.5 (3.81)	12	7.67 (2.85)
NH Other	73	9.97 (1.96)	11	12.7 (6.94)	7	12.7 (6.01)	2	0.64 (0.47)
Overall p-value				0.09		< 0.001		0.01
Education								
HS diploma or less/unknown	597	41.3 (2.45)	123	16.3 (2.09)	58	8.70 (1.77)	29	2.87 (0.74)
Some college	305	28.9 (2.37)	70	21.3 (3.95)	29	8.43 (2.35)	17	4.99 (2.00)
College graduate	254	29.9 (2.54)	18	4.33 (2.44)	13	5.11 (2.11)	3	0.41 (0.24)
Overall p-value				0.007		0.41		0.004
Family income (poverty:income ratio)								
< 130%	365	24.2 (1.90)	73	15.1 (2.35)	40	10.2 (1.92)	18	3.91 (1.17)
≥ 130%	702	68.0 (2.10)	116	13.5 (1.70)	52	6.68 (1.54)	27	2.44 (0.83)
Unknown/missing	89	7.80 (1.19)	22	16.5 (4.63)	8	7.07 (3.65)	4	1.83 (1.14)
Overall p-value				0.72		0.33		0.35
Pregnancy trimester								

First (0-3)	178	19.2 (1.88)	9	2.65 (1.23)	5	2.09 (1.18)	2	0.98 (0.87)
Second (4-6)	406	30.1 (2.20)	55	11.2 (2.21)	31	6.86 (1.84)	16	2.36 (0.84)
Third (7-10)	389	30.9 (2.21)	111	23.7 (3.24)	48	11.7 (2.83)	25	4.07 (1.63)
Unknown/missing	183	19.9 (1.94)	36	15.0 (4.33)	16	7.40 (2.21)	6	2.98 (1.50)
Overall p-value				< 0.001		0.02		0.38
Pre-pregnancy BMI (kg/m²)								
Underweight, <18.5	66	5.35 (1.05)	17	12.1 (4.56)	7	5.14 (2.48)	6	4.41 (2.33)
Normal, 18.5-24.9	609	52.4 (2.15)	113	13.8 (2.10)	53	7.05 (1.70)	30	3.20 (1.04)
Overweight, 25.0-29.9	265	21.7 (1.74)	49	18.5 (3.12)	23	8.81 (2.48)	9	2.63 (1.25)
Obese ≥30.0	216	20.5 (1.87)	32	10.7 (3.02)	17	8.11 (2.71)	4	1.28 (0.85)
Overall p-value				0.31		0.82		0.48

201 ^a Iron deficiency was defined based on total body iron < 0 mg/kg. Total body iron was calculated using ferritin and transferrin receptor
202 using Cook's equation ³⁰.

203 ^b Anemia was defined based on hemoglobin < 11 g/dL.

204 ^c IDA was defined as both total body iron < 0 mg/kg and hemoglobin < 11 g/dL.

205 ^d N values were non-weighted.

206 ^e Percentages and standard errors for all columns were weighted and analyzed using chi-square tests.

207 Abbreviations: BMI=Body mass index; HS=High school; IDA=Iron deficiency anemia; NH=Non-Hispanic; SE=Standard error.

208 **Iron Status by BMI Category**

209 Ferritin and total body iron concentrations were slightly lower in women with pre-pregnancy
210 BMI in the normal and overweight categories compared to the underweight and obese categories,
211 but these differences have very low confidence ($p > 0.10$; Fig 1). There were also no statistical or
212 meaningful differences between BMI groups in TfR or Hb. We tested if continuous pre-
213 pregnancy BMI (kg/m^2) was associated with concentrations of iron biomarkers (ferritin, TfR,
214 total body iron, and Hb), and we found no association in unadjusted or adjusted models ($p > 0.10$;
215 results not shown).

216

217 **Fig 1. Iron status biomarker concentrations by BMI category (n=1156).** Serum
218 concentrations of: A) Ferritin ($p = 0.11$), B) TfR ($p = 0.70$), C) Total Body Iron ($p = 0.13$), and
219 D) Hb ($p = 0.74$) stratified by BMI categories (Underweight, $< 18.5 \text{ kg}/\text{m}^2$; Normal, $18.5\text{-}24.9$
220 kg/m^2 ; Overweight, $25\text{-}29.9 \text{ kg}/\text{m}^2$; Obesity, $\geq 30 \text{ kg}/\text{m}^2$). Data are presented as adjusted least
221 squares means \pm 95% confidence intervals ($1.96 \times$ standard errors of the means). Differences
222 between groups were assessed using weighted multiple linear regression models adjusted for age,
223 race/ethnicity, education level, family income (PIR), and trimester of pregnancy and adjusted for
224 multiple comparisons using the Bonferroni method. Ferritin and transferrin receptor (TfR) were
225 log-transformed in the models to account for non-normal distributions. Means and confidence
226 intervals were exponentiated for presentation. Total body iron was calculated using Ferritin and
227 transferrin receptor using Cook's equation³⁰. Abbreviations: BMI=Body mass index (kg/m^2);
228 Ferritin=Ferritin; Hb=Hemoglobin; PIR=Poverty:income ratio; TfR=Transferrin receptor.

229

230 Similarly, we found no differences in the prevalence of ID (total body iron < 0 mg/kg),
231 anemia (Hb < 11 g/dL), or IDA by pre-pregnancy BMI (Table 2). However, because the number
232 of IDA cases was low within each BMI category, the estimates in adjusted models should be
233 considered unreliable and interpreted with caution. The number of cases for all outcomes was
234 also low in the underweight (BMI < 18.5 kg/m²) category.

235 **Table 2: Weighted prevalences and prevalence ratios and differences of iron deficiency and anemia status in pregnant women**
 236 **ages 18-49 by pre-pregnancy BMI from NHANES 1999-2010 (n = 1156).**

Pre-pregnancy BMI categories by iron status:	Prevalence [% (Standard Error)]	Cases (N)^a	Unadjusted Prevalence Ratio (95% CI)^b	Adjusted Prevalence Ratio (95% CI)^c	Adjusted Prevalence Difference [excess cases per 100 (95% CI)]
ID (Ferritin < 12 ug/L)					
Underweight BMI, < 18.5	15.5 (5.31)	18	0.75 (0.37, 1.52) ^d	0.78 (0.39, 1.57) ^d	-4.51 (-16.3, 7.25) ^d
Normal BMI, 18.5-24.9	20.6 (2.78)	156	Reference	Reference	Reference
Overweight BMI, 25-29.9	21.2 (4.18)	64	1.03 (0.64, 1.64)	0.98 (0.64, 1.51)	-0.43 (-9.32, 8.46)
Obese BMI, ≥ 30	15.5 (4.06)	38	0.75 (0.41, 1.38)	0.72 (0.41, 1.27)	-5.79 (-15.1, 3.53)
ID (TfR > 4.4 mg/L)					
Underweight BMI, < 18.5	12.5 (4.35)	16	0.72 (0.34, 1.49) ^d	0.97 (0.49, 1.93) ^d	-0.53 (-11.6, 10.6) ^d
Normal BMI, 18.5-24.9	17.4 (2.54)	110	Reference	Reference	Reference
Overweight BMI, 25-29.9	17.5 (2.91)	46	1.01 (0.63, 1.62)	1.09 (0.72, 1.64)	1.42 (-5.77, 8.62)
Obese BMI, ≥ 30	14.7 (3.26)	40	0.85 (0.52, 1.39)	0.93 (0.61, 1.41)	-1.24 (-7.90, 5.42)
ID (Total body iron < 0 mg/kg)^e					
Underweight BMI, < 18.5	12.7 (4.56)	17	0.91 (0.43, 1.92) ^d	0.88 (0.41, 1.89) ^d	-1.74 (-11.4, 7.94) ^d
Normal BMI, 18.5-24.9	13.9 (2.10)	113	Reference	Reference	Reference
Overweight BMI, 25-29.9	18.5 (3.12)	49	1.33 (0.86, 2.05)	1.27 (0.89, 1.82)	3.88 (-1.95, 9.70)
Obese BMI, ≥ 30	10.7 (3.02)	32	0.77 (0.40, 1.49)	0.75 (0.39, 1.45)	-3.49 (-11.0, 4.06)
Anemia (Hb < 11 g/dL)^f					
Underweight BMI, < 18.5	5.14 (2.48)	7	0.73 (0.25, 2.13) ^d	0.88 (0.28, 2.77) ^d	-0.90 (-8.57, 6.77) ^d
Normal BMI, 18.5-24.9	7.05 (1.70)	53	Reference	Reference	Reference
Overweight BMI, 25-29.9	8.81 (2.48)	23	1.25 (0.61, 2.55)	1.08 (0.53, 2.19)	0.58 (-4.98, 6.14)
Obese BMI, ≥ 30	8.11 (2.71)	17	1.15 (0.55, 2.43)	0.99 (0.49, 2.01)	-0.05 (-5.29, 5.19)
ID Anemia (Hb < 11 g/dL and Total body iron < 0 mg/kg)^f					
Underweight BMI, < 18.5	4.41 (2.33)	6	1.38 (0.40, 4.71) ^d	1.38 (0.39, 4.90) ^d	1.44 (-4.84, 7.72) ^d
Normal BMI, 18.5-24.9	3.20 (1.04)	30	Reference	Reference	Reference
Overweight BMI, 25-29.9	2.63 (1.25)	9	0.82 (0.29, 2.35)	0.62 (0.24, 1.57)	-1.44 (-4.01, 1.14)
Obese BMI, ≥ 30	1.28 (0.85)	4	0.40 (0.09, 1.70)	0.27 (0.08, 0.89)	-2.75 (-5.05, -0.44)

237 ^a N values represent non-weighted number of cases; all other analyses were weighted.

238 ^b Prevalence ratios and differences were calculated using Poisson regression models with robust error variance.

239 ^c The covariates included in all adjusted models were age, race/ethnicity, education level, family income, and trimester of pregnancy.
240 ^d Estimates for the underweight BMI (< 18 kg/m²) group may be unreliable because the number of cases was < 30 for all models ⁴⁷.
241 ^e Total body iron was calculated using ferritin and transferrin receptor using Cook's equation ³⁰.
242 ^f Estimates may be unreliable due to sample size of cases < 30 for some BMI categories ⁴⁷.
243 Abbreviations: BMI=Body mass index; CI=Confidence interval; Ferritin=Ferritin; ID=Iron deficiency; IDA=Iron deficiency anemia;
244 Hb=Hemoglobin; TfR=Transferrin receptor

245

246 **Discussion**

247 Based on NHANES data from 1999-2010, pre-pregnancy overweight and obesity were not
248 associated with increased prevalence of ID or anemia during pregnancy in this US population.
249 Although pre-pregnancy obesity is strongly linked to increased risk of adverse pregnancy
250 outcomes, based on our results, it was not associated with ID or anemia.

251 To our knowledge, the association between iron status and BMI has not been examined with
252 nationally representative data in US pregnant women using biomarkers of either the circulating
253 iron or storage iron components. The circulating iron component is measured with biomarkers
254 such as TfR, serum iron, or transferrin saturation. Two prior cross-sectional cohort studies
255 conducted in the US observed no association between circulating iron biomarkers and BMI
256 groups^{17,18}, which is similar to our findings. Of note, one of these studies¹⁸ was conducted in
257 adolescents (13-18 years of age) and the other¹⁷ was limited by a small sample size (n=15 per
258 group). Interestingly, studies from outside of the US have found contradictory results with some
259 finding no association between TfR and obesity^{19,22,48} and others observing that TfR
260 concentrations were higher (indicating poorer iron status) in women with obesity^{19-21,49}.

261 Our results for the storage iron component, measured by ferritin, are largely consistent with
262 other studies^{20,21,49}. However, one study¹⁸ found that higher concentrations of ferritin at mid-
263 gestation and delivery were associated with classes two and three of obesity (BMI 35-39.9 and \geq
264 40 kg/m²) compared with normal pre-pregnancy BMI. In the current study, we did not have a
265 large enough sample size to stratify by obesity class. In addition, although NHANES recorded
266 trimester at the time of assessment for each pregnant participant, there was not a large enough
267 sample size to test for interactions between BMI category and trimester in the current study.

268 In addition to its function as an iron storage biomarker, ferritin is an acute phase protein,
269 susceptible to inflammation, measured by CRP in the NHANES study. The prevalence of
270 inflammation based on CRP >5 mg/L in our sample was 48%, which is similar to results reported
271 by Mei et al. ⁹. Previous studies have observed higher concentrations of inflammatory markers
272 such as CRP, interleukin-6, leptin, and hepcidin in women with obesity compared with normal
273 weight ^{18,20}. In our study, pregnant women with obesity had significantly higher concentrations
274 of the inflammatory protein, CRP, (mean (standard error) = 13.2 (1.5) mg/L) than other BMI
275 categories (mean (standard error) = 6.6 (0.6) mg/L; $p < 0.001$), suggesting that elevated serum
276 CRP is more strongly related to obesity in this sample than with acute inflammatory response.
277 Others have found that chronic inflammation may be connected to lower ferritin concentrations
278 through the regulatory hormone hepcidin. Hepcidin increases when iron concentrations in
279 circulation are adequate or in the presence of inflammation ⁵⁰ and acts by blocking iron release
280 from storage into circulation via degradation of the efflux protein, ferroportin ⁵¹. This would
281 suggest that obesity-related inflammation would lead to lower circulating ferritin concentrations,
282 which was not supported by our findings. However, our results may be explained by the fact that
283 hepcidin rises only moderately in individuals with obesity when compared to those with serious
284 inflammatory diseases ⁵⁰. Testing this mechanism was outside the scope of our study, since
285 NHANES has not measured hepcidin in laboratory measures. Last, the functional iron
286 compartment, measured with Hb, was not associated with BMI categories in our sample, which
287 is consistent with prior studies ^{18,19,21,22}.

288 Overall, we did not find any meaningful association with iron status biomarkers and BMI
289 when adjusting for age, race/ethnicity, education level, family income, and trimester of
290 pregnancy. Although our results differed from other studies, there could be a variety of factors

291 explaining these differences. First, distinct populations may have different associations between
292 BMI and ID, and studies conducted in other countries may be measuring completely different
293 populations. Second, there may be other unmeasured confounding factors such as access to
294 medical care and food security status. For instance, access to medical care during pregnancy may
295 delay diagnosis of ID and anemia and in turn, prescription of iron supplements during critical
296 stages of pregnancy when it is needed most, and that pregnant women with food insecurity are
297 more likely to have both lower iron intake and iron deficiency ⁵². Last, prenatal iron
298 supplementation could also be a contributing factor to iron status. Analyses of NHANES data
299 from 1996 to 2006 ⁵³ show that 77% of pregnant women self-reported taking a supplement
300 containing iron (48 mg) in the previous 30 days, but previous studies have also found lower
301 supplement use and iron intake in non-Hispanic Black pregnant women ^{54,55}. Our work focused
302 on iron status (concentrations and prevalences) rather than dietary sources such as iron
303 supplementation, but based on prior evidence, we may infer that the majority of pregnant women
304 in our analysis took an iron supplement during pregnancy.

305 The prevalence of ID in this study, based on total body iron, was 14%, which was similar to
306 ID prevalence (also based on total body iron) observed in the Gupta et al., (16%) ⁷, and Mei et
307 al., (18%) ⁹, both previous NHANES studies. The prevalence of anemia in our study was 8%,
308 which was similar to the prevalence of 5% found by Mei et al. ⁹. Our estimate of IDA was also
309 similar to the 3% reported by Gupta et al. ⁷. Slight discrepancies in prevalence rates between
310 these studies may be explained by differing NHANES cycles included in analysis and differing
311 age ranges. In the study by Gupta et al., the same cycles were used, but the age range (12-49 yrs.)
312 was wider. The study by Mei et al. used fewer NHANES cycles (1999-2006) and included
313 women aged 15-39 yrs. Overall, NHANES studies, including our current study, have observed

314 that prevalence of ID is higher than prevalence of anemia and IDA. Total anemia prevalence (5-
315 8%) in pregnant women is low in the US, compared with the global prevalence of 37%⁵⁶.

316 **Strengths & Limitations**

317 This study's main strength is that it uses a nationally representative sample of US
318 pregnant women. Further, NHANES oversampled pregnant women during the 1999-2006 cycles
319 and used comprehensive methods to assess iron status including the total body iron indicator.
320 Our study has, however, some limitations. First, the cross-sectional design precludes establishing
321 a temporal relationship. Second, as in any observational study, residual confounding may be
322 present despite our effort to adjust our models, particularly due to not being able to include
323 parity. Third, pre-pregnancy weight was self-reported, which may misclassify maternal BMI.
324 Fourth, due to the cross-sectional nature of the survey, we were unable to calculate gestational
325 weight gain, which would have been more accurate in testing its association with iron status.
326 Another potential confounder is gestational diabetes, which is only collected in two out of the six
327 cycles included in this analysis, thus, we were unable to account for this factor. Fifth, the most
328 recent iron status biomarker data combined with full pregnancy data (trimester or gestational
329 age) in NHANES is over ten years old, and there is some evidence that it may overestimate the
330 prevalence of anemia in low-income women⁵⁷. Therefore, it is unknown whether these data are
331 representative of the current population. NHANES should consider future collection of both iron
332 status biomarkers and all variables needed to assess iron status during pregnancy. Last, the
333 number of cases of anemia and especially of IDA was small in the overall sample and even
334 smaller when stratified by BMI groups, making adjusted prevalence estimates less reliable and
335 requiring caution for interpretation.

336 **Conclusions**

337 Overweight and obesity are common, and the prevalence continues to rise in pregnant
338 women in the US. However, using the NHANES 1999-2010 cycles, we did not find women with
339 pre-pregnancy overweight or obesity to have an increased likelihood for ID or anemia during
340 pregnancy when compared to pre-pregnancy normal weight. Previous studies reporting an
341 association between BMI and iron status were conducted in different populations and may have
342 been confounded by other demographic factors. Given these results and the fact that prenatal iron
343 deficiency remains a significant public health concern, there is a need to continue collection of
344 high-quality national data on these biomarkers during pregnancy to assess progress over time in
345 alleviating maternal health disparities.

346

347 **Acknowledgements**

348 The authors would like to acknowledge the contribution of Elizabeth Soucy, who assisted
349 with the initial literature search for this project.

350

351 **References**

- 352 1. Sundararajan S, Rabe H. Prevention of iron deficiency anemia in infants and toddlers. *Pediatric*
353 *Research*. 2021;89(1):63–73. PMID: 32330927
- 354 2. Scholl TO. Maternal iron status: Relation to fetal growth, length of gestation, and iron endowment
355 of the neonate. *Nutrition Reviews*. 2011;69(SUPPL. 1):23–29. PMID: 22043878
- 356 3. Marchi J, Berg M, Dencker A, Olander EK, Begley C. Risks associated with obesity in pregnancy, for
357 the mother and baby: A systematic review of reviews. *Obesity Reviews*. 2015;16(8):621–638.
358 PMID: 26016557
- 359 4. Rasmussen KM. Association of maternal obesity before conception with poor lactation
360 performance. *Annual review of nutrition*. 2007;27:103–121. PMID: 17341160
- 361 5. Pfeiffer CM, Sternberg MR, Caldwell KL, Pan Y. Race-Ethnicity Is Related to Biomarkers of Iron and
362 Iodine Status after Adjusting for Sociodemographic and Lifestyle Variables in NHANES 2003–2006.
363 *The Journal of Nutrition*. 2013 Jun 1;143(6):977S-985S.

- 364 6. Driscoll AK, Gregory ECW. Increases in Prepregnancy Obesity: United States, 2016-2019. NCHS data
365 brief. 2020;(392):1–8. PMID: 33270551
- 366 7. Gupta PM, Hamner HC, Suchdev PS, Flores-Ayala R, Mei Z. Iron status of toddlers, nonpregnant
367 females, and pregnant females in the United States. *American Journal of Clinical Nutrition*.
368 2017;106(1d):1640S-1646S. PMID: 29070559
- 369 8. Miller EM. Iron status and reproduction in US women: National health and nutrition examination
370 survey, 1999-2006. *PLoS ONE*. 2014;9(11):1999–2006. PMID: 25375360
- 371 9. Mei Z, Cogswell ME, Looker AC, Pfeiffer CM, Cusick SE, Lacher DA, Grummer-Strawn LM.
372 Assessment of iron status in US pregnant women from the national health and nutrition
373 examination survey (NHANES), 1999-2006. *American Journal of Clinical Nutrition*.
374 2011;93(6):1312–1320. PMID: 21430118
- 375 10. Milman N. Iron and pregnancy--a delicate balance. *Ann Hematol*. 2006 Sep;85(9):559–565. PMID:
376 16691399
- 377 11. Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL. Prevalence of iron deficiency in the
378 United States. *Journal of the American Medical Association*. 1997;277(12):973–976. PMID:
379 9091669
- 380 12. Brannon PM, Taylor CL. Iron supplementation during pregnancy and infancy: Uncertainties and
381 implications for research and policy. *Nutrients*. 2017;9(12):1–17. PMID: 29210994
- 382 13. Pobebe RA, Setorglo J, Klevator M, Murray-Kolb LE. The prevalence of anemia and iron deficiency
383 among pregnant Ghanaian women, a longitudinal study. *PLoS ONE*. 2021;16(3 March):1–14. PMID:
384 33760869
- 385 14. Rockfield S, Chhabra R, Robertson M, Rehman N, Bisht R, Nanjundan M. Links between iron and
386 lipids: Implications in some major human diseases. *Pharmaceuticals*. 2018;11(4):1–14.
- 387 15. Cepeda-Lopez AC, Osendarp SJM, Melse-Boonstra A, Aeberli I, Gonzalez-Salazar F, Feskens E,
388 Villalpando S, Zimmermann MB. Sharply higher rates of iron deficiency in obese Mexican women
389 and children are predicted by obesity-related inflammation rather than by differences in dietary
390 iron intake. *American Journal of Clinical Nutrition*. 2011;93(5):975–983.
- 391 16. Wawer AA, Hodyl NA, Fairweather-Tait S, Froessler B. Are pregnant women who are living with
392 overweight or obesity at greater risk of developing iron deficiency/anaemia? *Nutrients*.
393 2021;13(5). PMID: 34067098
- 394 17. Dao MC, Sen S, Iyer C, Klebenov D, Meydani SN. Obesity during Pregnancy and Fetal Iron Status: is
395 Hepcidin the link? *J Perinatol*. 2013;33(3):177–181.
- 396 18. Cao C, Pressman EK, Cooper EM, Guillet R, Westerman M, O'Brien KO. Prepregnancy Body Mass
397 Index and Gestational Weight Gain Have No Negative Impact on Maternal or Neonatal Iron Status.
398 *Reproductive Sciences*. 2016;23(5):613–622. PMID: 26423600

- 399 19. Garcia-Valdes L, Campoy C, Hayes H, Florido J, Rusanova I, Miranda MT, McArdle HJ. The impact of
400 maternal obesity on iron status, placental transferrin receptor expression and hepcidin expression
401 in human pregnancy. *International Journal of Obesity*. Nature Publishing Group; 2015;39(4):571–
402 578. PMID: 25614087
- 403 20. Flynn AC, Begum S, White SL, Dalrymple K, Gill C, Alwan NA, Kiely M, Latunde-Dada G, Bell R, Briley
404 AL, Nelson SM, Oteng-Ntim E, Sandall J, Sanders TA, Whitworth M, Murray DM, Kenny LC, Poston
405 L. Relationships between maternal obesity and maternal and neonatal iron status. *Nutrients*.
406 2018;10(8):1–10. PMID: 30061547
- 407 21. Jones AD, Zhao G, Jiang YP, Zhou M, Xu G, Kaciroti N, Zhang Z, Lozoff B. Maternal obesity during
408 pregnancy is negatively associated with maternal and neonatal iron status. *Eur J Clin Nutr*. 2016
409 Jan 27; PMID: 26813939
- 410 22. Flores-Quijano ME, Vega-Sánchez R, Tolentino-Dolores MC, López-Alarcón MG, Flores-Urrutia MC,
411 López-Olvera AD, Talavera JO. Is associated with changes in iron nutrition status and its
412 homeostatic regulation in pregnancy. *Nutrients*. 2019;11(3):1–17. PMID: 30909605
- 413 23. NHANES - NCHS Research Ethics Review Board Approval [Internet]. National Center for Health
414 Statistics. 2019 [cited 2020 Dec 8]. Available from: <https://www.cdc.gov/nchs/nhanes/irba98.htm>
- 415 24. CDC. Laboratory procedure manual: ferritin in serum (NHANES 2005-2006) [Internet]. National
416 Center for Health Statistics. 2008 [cited 2020 Dec 8]. Available from:
417 https://wwwn.cdc.gov/nchs/data/nhanes/2005-2006/labmethods/fertin_d_met_roche.pdf
- 418 25. CDC. Laboratory procedure manual: ferritin in serum (NHANES 2007-2008) [Internet]. National
419 Center for Health Statistics. 2009. Available from: [https://wwwn.cdc.gov/nchs/data/nhanes/2007-
420 2008/labmethods/fertin_e_met_ferritin.pdf](https://wwwn.cdc.gov/nchs/data/nhanes/2007-2008/labmethods/fertin_e_met_ferritin.pdf)
- 421 26. CDC. Laboratory procedure manual: soluble transferrin receptor in serum (NHANES 2005-2006)
422 [Internet]. National Center for Health Statistics. 2008. Available from:
423 https://www.cdc.gov/NCHS/data/nhanes/nhanes_05_06/tfr_d_met_transferrin_receptor.pdf
- 424 27. CDC. Laboratory procedure manual: soluble transferrin receptor in serum (NHANES 2007-2008)
425 [Internet]. National Center for Health Statistics. 2009. Available from:
426 [https://wwwn.cdc.gov/nchs/data/nhanes/2007-
427 2008/labmethods/tfr_e_met_transferrin_receptor.pdf](https://wwwn.cdc.gov/nchs/data/nhanes/2007-2008/labmethods/tfr_e_met_transferrin_receptor.pdf)
- 428 28. CDC. Laboratory procedure manual: ferritin in serum (NHANES 2009-2010) [Internet]. National
429 Center for Health Statistics. 2012. Available from: [https://wwwn.cdc.gov/nchs/data/nhanes/2009-
430 2010/labmethods/fertin_f_met_ferritin.pdf](https://wwwn.cdc.gov/nchs/data/nhanes/2009-2010/labmethods/fertin_f_met_ferritin.pdf)
- 431 29. CDC. Laboratory procedure manual: soluble transferrin receptor in serum (NHANES 2009-2010)
432 [Internet]. National Center for Health Statistics. 2012. Available from:
433 [https://wwwn.cdc.gov/nchs/data/nhanes/2009-
434 2010/labmethods/tfr_f_met_transferrin_receptor.pdf](https://wwwn.cdc.gov/nchs/data/nhanes/2009-2010/labmethods/tfr_f_met_transferrin_receptor.pdf)
- 435 30. Cook JD, Flowers CH, Skikne BS. The quantitative assessment of body iron. *Blood*. 2003 May
436 1;101(9):3359–3363. PMID: 12521995

- 437 31. Centers for Disease Control and Prevention. Recommendations to Prevent and Control Iron
438 Deficiency in the United States [Internet]. 1998 Apr p. 1–36. Report No.: 47 (RR–3). Available from:
439 <https://www.cdc.gov/mmwr/preview/mmwrhtml/00051880.htm>
- 440 32. Kolbe-Busch S, Lotz J, Hafner G, Blanckaert NJC, Claeys G, Togni G, Carlsen J, Röddiger R, Thomas L.
441 Multicenter evaluation of a fully mechanized soluble transferrin receptor assay on the Hitachi and
442 cobas integra analyzers. the determination of reference ranges. *Clin Chem Lab Med*. 2002
443 May;40(5):529–536. PMID: 12113300
- 444 33. CDC 1999-2000. Laboratory Procedure Manual. CBC with five-part differential NHANES 1999-2000
445 [Internet]. [cited 2023 Oct 24]. Available from:
446 https://www.cdc.gov/nchs/data/nhanes/nhanes_99_00/lab25_met_complete_blood_count.pdf
- 447 34. CDC 2007-2008. Laboratory Procedure Manual. CBC with five-part differential NHANES 2007-2008.
- 448 35. ACOG Practice Bulletin. Anemia in Pregnancy: ACOG Practice Bulletin, Number 233. *Obstet*
449 *Gynecol*. 2021 Aug 1;138(2):e55–e64. PMID: 34293770
- 450 36. CDC. Laboratory procedure manual: C-reactive protein in serum (NHANES 2005-2006) [Internet].
451 National Center for Health Statistics. 2007. Available from:
452 https://wwwn.cdc.gov/nchs/data/nhanes/2005-2006/labmethods/crp_d_met_protein.pdf
- 453 37. CDC. Laboratory procedure manual: C-reactive protein in serum (NHANES 2007-2008) [Internet].
454 National Center for Health Statistics. 2007. Available from:
455 https://wwwn.cdc.gov/nchs/data/nhanes/2007-2008/labmethods/crp_e_met.pdf
- 456 38. CDC. Laboratory procedure manual: C-reactive protein in serum (NHANES 2009-2010) [Internet].
457 National Center for Health Statistics. 2011. Available from:
458 https://wwwn.cdc.gov/nchs/data/nhanes/2009-2010/labmethods/crp_f_met.pdf
- 459 39. Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, Bienvenu J, Blaabjerg O, Blirup-Jensen S,
460 Carlström A, Petersen PH, Johnson AM, Milford-Ward A, Ritchie RF, Svendsen PJ, Whicher J.
461 Consensus of a group of professional societies and diagnostic companies on guidelines for interim
462 reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP
463 Reference Material (CRM 470). International Federation of Clinical Chemistry. Community Bureau
464 of Reference of the Commission of the European Communities. College of American Pathologists.
465 *Eur J Clin Chem Clin Biochem*. 1996 Jun;34(6):517–520. PMID: 8831057
- 466 40. Namaste SM, Rohner F, Huang J, Bhushan NL, Flores-Ayala R, Kupka R, Mei Z, Rawat R, Williams
467 AM, Raiten DJ, Northrop-Clewes CA, Suchdev PS. Adjusting ferritin concentrations for
468 inflammation: Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia
469 (BRINDA) project. *Am J Clin Nutr*. 2017 Jul;106(Suppl 1):359S-371S. PMCID: PMC5490647
- 470 41. Namaste SML, Ou J, Williams AM, Young MF, Yu EX, Suchdev PS. Adjusting iron and vitamin A
471 status in settings of inflammation: a sensitivity analysis of the Biomarkers Reflecting Inflammation
472 and Nutritional Determinants of Anemia (BRINDA) approach. *The American Journal of Clinical*
473 *Nutrition*. 2020 Aug 1;112(Supplement_1):458S-467S.

- 474 42. Luo H, Geng J, Zeiler M, Nieckula E, Sandalinas F, Williams A, Young MF, Suchdev PS. A Practical
475 Guide to Adjust Micronutrient Biomarkers for Inflammation Using the BRINDA Method. *J Nutr.*
476 2023 Apr;153(4):1265–1272. PMID: PMC10202121
- 477 43. Acharya S, Beard JL, Davidson FR, Davidsson L, Hertrampf ED, Jacobs M, Lynch SR, Stoltzfus RJ.
478 Why iron is important and what do do about it: a new perspective. Washington (DC), INACG
479 Secretariat; 2002 p. 1–50.
- 480 44. WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert
481 Committee. *World Health Organ Tech Rep Ser.* 1995;854:1–452. PMID: 8594834
- 482 45. Mei Z, Addo OY, Jefferds ME, Sharma AJ, Flores-Ayala RC, Brittenham GM. Physiologically based
483 serum ferritin thresholds for iron deficiency in children and non-pregnant women: a US National
484 Health and Nutrition Examination Surveys (NHANES) serial cross-sectional study. *The Lancet*
485 *Haematology.* 2021 Aug;8(8):e572–e582.
- 486 46. U.S. Department of Agriculture, Food and Nutrition Service. WIC eligibility requirements | USDA-
487 FNS [Internet]. 2020 [cited 2019 Aug 23]. Available from: [https://www.fns.usda.gov/wic/wic-](https://www.fns.usda.gov/wic/wic-eligibility-requirements)
488 [eligibility-requirements](https://www.fns.usda.gov/wic/wic-eligibility-requirements)
- 489 47. Parker JD, Talih M, Malec DJ, Beresovsky V, Carroll M, Gonzalez JF, Hamilton BE, Ingram DD,
490 Kochanek K, McCarty F, Moriarity C, Shimizu I, Strashny A, Ward BW. National Center for Health
491 Statistics Data Presentation Standards for Proportions. *Vital Health Stat 2.* 2017 Aug;(175):1–22.
492 PMID: 30248016
- 493 48. Vega-Sánchez R, Tolentino-Dolores MC, Cerezo-Rodríguez B, Chehaibar-Besil G, Flores-Quijano ME.
494 Erythropoiesis and Red Cell Indices Undergo Adjustments during Pregnancy in Response to
495 Maternal Body Size but not Inflammation. *Nutrients.* Multidisciplinary Digital Publishing Institute;
496 2020 Apr;12(4):975.
- 497 49. Flores-Quijano ME, Montalvo-Velarde I, Vital-Reyes VS, Rodríguez-Cruz M, Rendón-Macías ME,
498 López-Alarcón M. Longitudinal Analysis of the Interaction Between Obesity and Pregnancy on Iron
499 Homeostasis: Role of Hepcidin. *Arch Med Res.* 2016 Oct;47(7):550–556. PMID: 28262197
- 500 50. Tussing-Humphreys L, Pustacioglu C, Nemeth E, Braunschweig C. Rethinking Iron Regulation and
501 Assessment in Iron Deficiency, Anemia of Chronic Disease, and Obesity: Introducing Hepcidin. *J*
502 *Acad Nutr Diet.* 2012 Mar;112(3):391–400. PMID: PMC3381289
- 503 51. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Heparin
504 Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization. *Science.*
505 2004 Dec 17;306(5704):2090–2093. PMID: 15514116
- 506 52. Park CY, Eicher-Miller HA. Iron deficiency is associated with food insecurity in pregnant females in
507 the United States: National Health and Nutrition Examination Survey 1999-2010. *Journal of the*
508 *Academy of Nutrition and Dietetics.* 2014 Dec 1;114(12):1967–1973.
- 509 53. Branum AM, Bailey R, Singer BJ. Dietary supplement use and folate status during pregnancy in the
510 United States. *J Nutr.* 2013 Apr;143(4):486–492. PMID: PMC4745881

- 511 54. Cogswell ME, Kettel-Khan L, Ramakrishnan U. Iron Supplement Use among Women in the United
512 States: Science, Policy and Practice. *J Nutr.* 2003 Jun 1;133(6):1974S-1977S.
- 513 55. Liu J, Zhu X, Fulda KG, Chen S, Tao MH. Comparison of Dietary Micronutrient Intakes by Body
514 Weight Status among Mexican-American and Non-Hispanic Black Women Aged 19–39 Years: An
515 Analysis of NHANES 2003–2014. *Nutrients.* Multidisciplinary Digital Publishing Institute; 2019
516 Dec;11(12):2846.
- 517 56. WHO. Anaemia in women and children [Internet]. World Health Organization. 2021 [cited 2023
518 Aug 12]. Available from:
519 https://www.who.int/data/gho/data/themes/topics/anaemia_in_women_and_children
- 520 57. Kanu FA, Hamner HC, Scanlon KS, Sharma AJ. Anemia Among Pregnant Women Participating in the
521 Special Supplemental Nutrition Program for Women, Infants, and Children - United States, 2008-
522 2018. *MMWR Morb Mortal Wkly Rep.* 2022 Jun 24;71(25):813–819. PMID: 35737575
- 523
- 524





525 **Supporting Information**

526 **S1 Table: Weighted medians and prevalences of inflammation, iron, and anemia**
527 **biomarkers in pregnant women of reproductive age (18-49 years of age) from the NHANES**
528 **(1999-2010) study (n=1156).**

529 **S2 Table: Weighted prevalences and prevalence ratios and differences of iron deficiency**
530 **and anemia status in pregnant women ages 18-49 by race/ethnicity from NHANES 1999-**
531 **2010 (n = 1156).**

532 **S3 Table: Weighted prevalences and prevalence ratios and differences of iron deficiency**
533 **and anemia status in pregnant women ages 18-49, by race/ethnicity from NHANES 1999-**
534 **2010 (n=1156) using Mexican American and Hispanic Other categories.**

535



medRxiv preprint doi: <https://doi.org/10.1101/2024.03.07.24309918>; this version posted March 9, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Figure 1